AMRX AMNEAL PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AMNEAL PHARMACEUTICALS INC reported revenue of $796M (up 9.9% from a year earlier), net income of $57.7M and diluted EPS of $0.18; over the last four quarters revenue was $3.12B and net income $157M; for the fiscal year ended December 2025 revenue was $3.02B, up 8.0% on the year before.

AMRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.02B, gross profit $1.11B, operating income $394M, net income $72.1M (margin 2.4%), EPS $0.22
• Fiscal year ended Dec 2024: revenue $2.79B, gross profit $1.02B, operating income $249M, net income −$117M (margin -4.2%), EPS −$0.38
• Fiscal year ended Dec 2023: revenue $2.39B, gross profit $821M, operating income $204M, net income −$84.0M (margin -3.5%), EPS −$0.48
• Fiscal year ended Dec 2022: revenue $2.21B, gross profit $785M, operating income −$94.9M, net income −$271M (margin -12.2%), EPS −$0.86
• Fiscal year ended Dec 2021: revenue $2.09B, gross profit $769M, operating income $153M, net income $13.2M (margin 0.6%), EPS $0.07

AMRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $796M (up 9.9% year over year), net income $57.7M, EPS $0.18
• Quarter ended Mar 31, 2026: revenue $723M (up 3.9% year over year), net income $62.3M, EPS $0.19
• Quarter ended Dec 31, 2025 (from the annual report): revenue $814M (up 11.5% year over year), net income $35.1M, EPS $0.10
• Quarter ended Sep 30, 2025: revenue $785M (up 11.7% year over year), net income $2.37M, EPS $0.01
• Quarter ended Jun 30, 2025: revenue $725M (up 3.2% year over year), net income $22.4M, EPS $0.07
• Quarter ended Mar 31, 2025: revenue $695M (up 5.5% year over year), net income $12.2M, EPS $0.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $731M (up 18.4% year over year), net income −$31.1M, EPS −$0.10
• Quarter ended Sep 30, 2024: revenue $702M (up 13.3% year over year), net income −$156K, EPS $0.00
• Quarter ended Jun 30, 2024: revenue $702M (up 17.1% year over year), net income $5.99M, EPS $0.02
• Quarter ended Mar 31, 2024: revenue $659M (up 18.2% year over year), net income −$91.6M, EPS −$0.30
• Quarter ended Dec 31, 2023 (from the annual report): revenue $617M (up 1.2% year over year), net income −$98.6M, EPS −$0.57
• Quarter ended Sep 30, 2023: revenue $620M (up 13.7% year over year), net income $9.68M, EPS $0.06
• Quarter ended Jun 30, 2023: revenue $599M (up 7.1% year over year), net income $11.9M, EPS $0.08
• Quarter ended Mar 31, 2023: revenue $558M (up 12.0% year over year), net income −$6.94M, EPS −$0.05
• Quarter ended Dec 31, 2022 (from the annual report): revenue $610M (up 13.6% year over year), net income −$12.0M, EPS −$0.03
• Quarter ended Sep 30, 2022: revenue $546M (up 3.2% year over year), net income −$7.61M, EPS −$0.02
• Quarter ended Jun 30, 2022: revenue $559M (up 4.5% year over year), net income −$242M, EPS −$0.80
• Quarter ended Mar 31, 2022: revenue $498M (up 0.9% year over year), net income −$8.82M, EPS −$0.01
• Quarter ended Dec 31, 2021 (from the annual report): revenue $537M, net income −$21.8M, EPS −$0.04
• Quarter ended Sep 30, 2021: revenue $529M, net income −$7.78M, EPS −$0.03

AMRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $340M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $295M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $346M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $65.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $242M, share buybacks n/a

AMRX balance sheet

• Jun 30, 2026: cash $128M, total assets $3.78B, total liabilities n/a, shareholders' equity $33.0M, long-term debt $2.56B
• Mar 31, 2026: cash $198M, total assets $3.54B, total liabilities n/a, shareholders' equity −$45.4M, long-term debt $2.57B
• Dec 31, 2025: cash $282M, total assets $3.68B, total liabilities n/a, shareholders' equity −$70.8M, long-term debt $2.57B
• Sep 30, 2025: cash $201M, total assets $3.60B, total liabilities n/a, shareholders' equity −$109M, long-term debt $2.57B
• Jun 30, 2025: cash $71.5M, total assets $3.42B, total liabilities n/a, shareholders' equity −$112M, long-term debt $2.15B
• Mar 31, 2025: cash $59.2M, total assets $3.37B, total liabilities n/a, shareholders' equity −$132M, long-term debt $2.15B
• Dec 31, 2024: cash $111M, total assets $3.50B, total liabilities n/a, shareholders' equity −$109M, long-term debt $2.16B
• Sep 30, 2024: cash $74.0M, total assets $3.46B, total liabilities n/a, shareholders' equity −$93.4M, long-term debt $2.17B

What is AMRX's revenue?

AMNEAL PHARMACEUTICALS INC reported $3.12B of revenue over its last four quarters, through June 30, 2026.

Is AMRX profitable?

Yes. AMNEAL PHARMACEUTICALS INC earned $157M over the last four quarters.

What is AMRX's EPS?

Diluted earnings per share over the last four quarters were $0.48; $0.18 in the latest quarter.

AMRX ownership and insider trades · All stocks